AR064014A1 - Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina - Google Patents
Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestinaInfo
- Publication number
- AR064014A1 AR064014A1 ARP070105286A ARP070105286A AR064014A1 AR 064014 A1 AR064014 A1 AR 064014A1 AR P070105286 A ARP070105286 A AR P070105286A AR P070105286 A ARP070105286 A AR P070105286A AR 064014 A1 AR064014 A1 AR 064014A1
- Authority
- AR
- Argentina
- Prior art keywords
- strogen
- layer
- tablets
- progestine
- serm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a tabletas bi-capas que comprenden al menos, un estrogeno en una primera capa y un agente terapéutico en una segunda capa, y proceso para su preparacion. Reivindicacion 1: Una tableta bi-capa caracterizada porque comprende: (a) una primera capa que comprende al menos un estrogeno; y (b) una segunda capa que comprende uno o más agentes terapéuticos seleccionados del grupo que consiste de un modulador selectivo del receptor de estrogeno y un agente progestacional. Reivindicacion 4: Una tableta como se reivindica de conformidad con cualquiera de las reivindicaciones precedentes, caracterizada porque dicha segunda capa comprende uno o más agentes terapéuticos seleccionados del grupo que consiste de acetato de medroxiprogesterona y 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxi-fenil)-3-metil-1H-indol-5-ol, o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86771506P | 2006-11-29 | 2006-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064014A1 true AR064014A1 (es) | 2009-03-04 |
Family
ID=39456367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105286A AR064014A1 (es) | 2006-11-29 | 2007-11-28 | Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina |
Country Status (17)
Country | Link |
---|---|
US (1) | US20080175905A1 (es) |
EP (1) | EP2086550A2 (es) |
JP (1) | JP2010511062A (es) |
KR (1) | KR20090086100A (es) |
CN (1) | CN101541326A (es) |
AR (1) | AR064014A1 (es) |
AU (1) | AU2007325207A1 (es) |
BR (1) | BRPI0719675A2 (es) |
CA (1) | CA2670544A1 (es) |
CL (1) | CL2007003429A1 (es) |
IL (1) | IL198823A0 (es) |
MX (1) | MX2009005724A (es) |
PE (1) | PE20081301A1 (es) |
RU (1) | RU2009117201A (es) |
TW (1) | TW200831139A (es) |
WO (1) | WO2008067387A2 (es) |
ZA (1) | ZA200903725B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010515758A (ja) * | 2007-01-12 | 2010-05-13 | ワイス エルエルシー | 錠剤中錠剤組成物 |
US20090324714A1 (en) * | 2008-06-27 | 2009-12-31 | Wyeth | Dual adhesive technology |
WO2011056532A2 (en) * | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
US8501690B2 (en) | 2010-04-30 | 2013-08-06 | John G. Stark | Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue |
WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
WO2012164096A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
IN2014DN03247A (es) * | 2011-11-04 | 2015-05-22 | Agile Therapeutics Inc | |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
MA39105B1 (fr) * | 2013-12-12 | 2018-05-31 | Donesta Bioscience B V | Unité de dosage solide se désintégrant par voie orale contenant un constituant estétrol |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
MX2017016276A (es) | 2015-06-18 | 2018-06-19 | Mithra Pharmaceuticals S A | Unidad de dosificacion orodispersable que contiene un componente estetrol. |
TN2017000497A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
MA44205B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
AU2002242339A1 (en) * | 2002-03-14 | 2003-09-29 | Watson Pharmaceuticals, Inc. | Progesterone oral drug delivery system |
EP1531807A4 (en) * | 2002-06-13 | 2007-10-31 | Wyeth Corp | Bazedoxifene TREATMENT SCHEMES |
AU2005251793B2 (en) * | 2004-06-07 | 2010-07-15 | Wyeth | Sugar coatings and methods therefor |
RU2007132852A (ru) * | 2005-03-31 | 2009-05-10 | Вайет (Us) | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение |
US20070003623A1 (en) * | 2005-06-29 | 2007-01-04 | Wyeth | Formulations of conjugated estrogens and bazedoxifene |
EP2079454A2 (en) * | 2006-11-07 | 2009-07-22 | Wyeth a Corporation of the State of Delaware | Sugar coatings and methods therefor |
-
2007
- 2007-11-28 EP EP07871621A patent/EP2086550A2/en not_active Withdrawn
- 2007-11-28 CN CNA2007800441214A patent/CN101541326A/zh active Pending
- 2007-11-28 PE PE2007001673A patent/PE20081301A1/es not_active Application Discontinuation
- 2007-11-28 CL CL200703429A patent/CL2007003429A1/es unknown
- 2007-11-28 RU RU2009117201/15A patent/RU2009117201A/ru not_active Application Discontinuation
- 2007-11-28 BR BRPI0719675-0A2A patent/BRPI0719675A2/pt not_active Application Discontinuation
- 2007-11-28 CA CA002670544A patent/CA2670544A1/en not_active Abandoned
- 2007-11-28 AR ARP070105286A patent/AR064014A1/es unknown
- 2007-11-28 TW TW096145178A patent/TW200831139A/zh unknown
- 2007-11-28 JP JP2009539461A patent/JP2010511062A/ja not_active Withdrawn
- 2007-11-28 MX MX2009005724A patent/MX2009005724A/es unknown
- 2007-11-28 AU AU2007325207A patent/AU2007325207A1/en not_active Abandoned
- 2007-11-28 KR KR1020097012025A patent/KR20090086100A/ko not_active Application Discontinuation
- 2007-11-28 US US11/946,586 patent/US20080175905A1/en not_active Abandoned
- 2007-11-28 WO PCT/US2007/085773 patent/WO2008067387A2/en active Application Filing
-
2009
- 2009-05-19 IL IL198823A patent/IL198823A0/en unknown
- 2009-05-28 ZA ZA200903725A patent/ZA200903725B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101541326A (zh) | 2009-09-23 |
WO2008067387A2 (en) | 2008-06-05 |
AU2007325207A1 (en) | 2008-06-05 |
MX2009005724A (es) | 2009-06-12 |
RU2009117201A (ru) | 2011-01-10 |
EP2086550A2 (en) | 2009-08-12 |
BRPI0719675A2 (pt) | 2013-12-24 |
PE20081301A1 (es) | 2008-10-01 |
ZA200903725B (en) | 2010-04-28 |
JP2010511062A (ja) | 2010-04-08 |
US20080175905A1 (en) | 2008-07-24 |
IL198823A0 (en) | 2010-02-17 |
WO2008067387A3 (en) | 2008-08-07 |
KR20090086100A (ko) | 2009-08-10 |
CL2007003429A1 (es) | 2008-04-11 |
TW200831139A (en) | 2008-08-01 |
CA2670544A1 (en) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064014A1 (es) | Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina | |
JP2007527914A5 (es) | ||
CL2011000935A1 (es) | Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor. | |
WO2007038669A3 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
WO2005097064A3 (en) | Taste-masked drugs in rupturing multiparticulates | |
CL2008001983A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras. | |
BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
AR054806A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
CL2007003331A1 (es) | Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente. | |
CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
AR059357A1 (es) | Formulaciones farmaceuticas | |
CL2007003272A1 (es) | Compuestos derivados de pirazol y triazol sustituidos; y composicion farmaceutica, util para el tratamiento de una enfermedad proliferativa celular. | |
JP2008013542A5 (es) | ||
EA201100229A1 (ru) | Фармацевтическая композиция для лечения верхнего отдела пищеварительного тракта | |
CO6220900A2 (es) | Forma dosificadora novedosa | |
AR065342A1 (es) | Composiciones farmaceuticas que contienen fumarato de quetiapina | |
CL2007000680A1 (es) | Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc. | |
UY29445A1 (es) | Composiciones para la transmisión transmucosa oral de la metformina | |
DE602006000102D1 (de) | Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
CL2014001935A1 (es) | Sistema para administrar farmacos que comprende al menos un nucleo que comprende una o mas sustancias terapeuticamente activas, una membrana que encierra al nucleo y una capa intermedia de material sustancialmente inerte que consiste en silice, silices pirogena y precipitada y talco, entre nucleo y membrana o entre membranas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |